Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582836 | 0.90 | ACHE (0.43) | CASP1CASP7HSD17B10S1PR1S1PR3 | |
| SCHEMBL5582751 | 0.75 | CASP1 (0.46) | LMNACASP1CASP7HSD17B10KDM4E | |
| SCHEMBL10670021 | 0.71 | KDM4E (0.42) | S1PR1S1PR3KDM4E | |
| SCHEMBL5582939 | 0.71 | MCHR1 (0.57) | MAPT | |
| SCHEMBL5582887 | 0.70 | MCHR1 (0.51) | LMNANR1H2MC4RKDM4EMAPT | |
| SCHEMBL5582743 | 0.70 | ACHE (0.40) | LMNACASP1CASP7HSD17B10MAPT | |
| SCHEMBL4758225 | 0.70 | NR1H2 (0.64) | LMNANR1H2MC4RKDM4EMAPT | |
| SCHEMBL3396724 | 0.70 | NR1H2 (0.60) | LMNANR1H2MC4RKDM4EMAPT | |
| SCHEMBL6273608 | 0.68 | NR1H2 (0.61) | LMNANR1H2MC4RKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL6268461 | 0.67 | NR1H2 (0.60) | LMNANR1H2MC4RKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | LMNA 4047/4885NR1H2 325/4885CASP1 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.